Cargando…

Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer

Detalles Bibliográficos
Autores principales:	Ghiringhelli, Francois, Truntzer, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290964/ https://www.ncbi.nlm.nih.gov/pubmed/30564294 http://dx.doi.org/10.18632/oncotarget.26389

Ejemplares similares

FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report
por: Roussot, Nicolas, et al.
Publicado: (2023)

Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer
por: Galland, Loïck, et al.
Publicado: (2021)

Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy
por: Ballot, Elise, et al.
Publicado: (2020)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
por: Fumet, Jean-David, et al.
Publicado: (2020)

The Highways
Publicado: (1893)

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type
por: Dalens, Lorraine, et al.
Publicado: (2023)

Highway Improvements
Publicado: (1889)

Public Highways
Publicado: (1893)

Driving the precision medicine highway: community health workers and patient navigators
por: Ramos, Irma N., et al.
Publicado: (2019)

Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma
por: Lecuelle, Julie, et al.
Publicado: (2021)

Hijackers on the open access highway
por: Watson, Roger
Publicado: (2015)

Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers
por: Medjebar, Soleine, et al.
Publicado: (2020)

What biomarkers (if any) for precise medicine?
por: Strano, Sabrina, et al.
Publicado: (2015)

Precision medicine in breast cancer: reality or utopia?
por: Bettaieb, Ali, et al.
Publicado: (2017)

CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
por: Liu, Delong
Publicado: (2019)

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
por: Kaderbhaï, Courèche, et al.
Publicado: (2019)

Cell lines and immune classification of glioblastoma define patient’s prognosis
por: Klopfenstein, Quentin, et al.
Publicado: (2019)

TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer
por: Lecuelle, Julie, et al.
Publicado: (2021)

Molecular biology tools for precision medicine in managing lung cancer
por: Mahesh, PA
Publicado: (2018)

Genomics and precision medicine and their impact on endocrinology
por: Stratakis, Constantine A
Publicado: (2023)

From genomic medicine to precision medicine: highlights of 2015
por: Auffray, Charles, et al.
Publicado: (2016)

A decade of Genome Medicine: toward precision medicine
por: Begum, Rabia
Publicado: (2019)

Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
por: Conway, Jake R., et al.
Publicado: (2018)

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
por: Lecuelle, Julie, et al.
Publicado: (2022)

In Vivo Biomarker Imaging: Paving the Way for Precision Medicine
por: Liu, Guanshu, et al.
Publicado: (2023)

Genomic biomarkers: Unveiling the potential for precise cancer therapy response
por: Kaur, Gurjeet, et al.
Publicado: (2023)

Networking and electronic highway
por: Flückiger, François
Publicado: (1996)

Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma
por: Aarnink, Anne, et al.
Publicado: (2018)

From Biomarkers to Precision Medicine in Neurodegenerative Diseases: Where Are We?
por: Tondo, Giacomo, et al.
Publicado: (2022)

Utility of exome sequencing in routine care for metastatic colorectal cancer
por: D'Agay, Melchior De Giraud, et al.
Publicado: (2021)

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing
por: Galland, Loïck, et al.
Publicado: (2022)

Understanding the Precision in “Precision Medicine”
por: Chabner, Bruce A.
Publicado: (2016)

Highways
por: Benedict, A. L.
Publicado: (1917)

Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine
por: Pons-Tostivint, Elvire, et al.
Publicado: (2022)

Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES images
por: Le Page, Anne Laure, et al.
Publicado: (2021)

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
por: Liu, Xiaoming, et al.
Publicado: (2017)

The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment
por: Macias, Rocio I. R., et al.
Publicado: (2023)

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
por: Limagne, Emeric, et al.
Publicado: (2019)

Precision medicine()
por: Nakanishi, Marcio
Publicado: (2018)

Precision Medicine
por: Pinho, João Renato Rebello
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eft4cu6ho9it8vntsrv6jfmkl7